Magnus Johannesson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1801407/publications.pdf

Version: 2024-02-01

301 papers 39,286 citations

89 h-index ³⁹¹⁵
177
g-index

320 all docs

 $\begin{array}{c} 320 \\ \\ \text{docs citations} \end{array}$

times ranked

320

37847 citing authors

#	Article	IF	CITATIONS
1	2D:4D and Self-Employment: A Preregistered Replication Study in a Large General Population Sample. Entrepreneurship Theory and Practice, 2022, 46, 21-43.	10.2	7
2	Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals. Nature Genetics, 2022, 54, 437-449.	21.4	215
3	A creative destruction approach to replication: Implicit work and sex morality across cultures. Journal of Experimental Social Psychology, 2021, 93, 104060.	2.2	22
4	#EEGManyLabs: Investigating the replicability of influential EEG experiments. Cortex, 2021, 144, 213-229.	2.4	52
5	Predicting replicabilityâ€"Analysis of survey and prediction market data from large-scale forecasting projects. PLoS ONE, 2021, 16, e0248780.	2.5	14
6	POS0348â€GENETIC SUSCEPTIBILITY VARIANTS FOR RHEUMATOID ARTHRITIS ARE NOT ASSOCIATED WITH EAR REMISSION; A MULTI-COHORT STUDY. Annals of the Rheumatic Diseases, 2021, 80, 403.1-404.	≀LY. ₉	0
7	2D:4D does not predict economic preferences: Evidence from a large, representative sample. Journal of Economic Behavior and Organization, 2021, 185, 390-401.	2.0	15
8	Resource profile and user guide of the Polygenic Index Repository. Nature Human Behaviour, 2021, 5, 1744-1758.	12.0	63
9	Using prediction markets to predict the outcomes in the Defense Advanced Research Projects Agency's next-generation social science programme. Royal Society Open Science, 2021, 8, 181308.	2.4	4
10	Identification of 371 genetic variants for age at first sex and birth linked to externalising behaviour. Nature Human Behaviour, 2021, 5, 1717-1730.	12.0	62
11	Are women more generous than men? A meta-analysis. Journal of the Economic Science Association, 2021, 7, 1-18.	2.3	26
12	Consensus-based guidance for conducting and reporting multi-analyst studies. ELife, 2021, 10, .	6.0	22
13	Comparing meta-analyses and preregistered multiple-laboratory replication projects. Nature Human Behaviour, 2020, 4, 423-434.	12.0	129
14	Creative destruction in science. Organizational Behavior and Human Decision Processes, 2020, 161, 291-309.	2.5	36
15	Many Labs 5: Testing Pre-Data-Collection Peer Review as an Intervention to Increase Replicability. Advances in Methods and Practices in Psychological Science, 2020, 3, 309-331.	9.4	42
16	Are replication rates the same across academic fields? Community forecasts from the DARPA SCORE programme. Royal Society Open Science, 2020, 7, 200566.	2.4	21
17	Variability in the analysis of a single neuroimaging dataset by many teams. Nature, 2020, 582, 84-88.	27.8	634
18	The intuitive cooperation hypothesis revisited: a meta-analytic examination of effect size and between-study heterogeneity. Journal of the Economic Science Association, 2020, 6, 26-42.	2.3	34

#	Article	IF	Citations
19	Crowdsourcing hypothesis tests: Making transparent how design choices shape research results Psychological Bulletin, 2020, 146, 451-479.	6.1	87
20	fMRI data of mixed gambles from the Neuroimaging Analysis Replication and Prediction Study. Scientific Data, 2019, 6, 106.	5.3	30
21	The digit ratio (2D:4D) and economic preferences: no robust associations in a sample of 330 women. Journal of the Economic Science Association, 2019, 5, 149-169.	2.3	15
22	Associations of autozygosity with a broad range of human phenotypes. Nature Communications, 2019, 10, 4957.	12.8	84
23	Predicting the replicability of social science lab experiments. PLoS ONE, 2019, 14, e0225826.	2.5	43
24	Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. Nature Genetics, 2019, 51, 245-257.	21.4	536
25	Predicting replication outcomes in the Many Labs 2 study. Journal of Economic Psychology, 2019, 75, 102117.	2.2	44
26	Multi-trait analysis of genome-wide association summary statistics using MTAG. Nature Genetics, 2018, 50, 229-237.	21.4	700
27	An Experimental Investigation of Election Promises. Political Psychology, 2018, 39, 685-705.	3.6	26
28	Hormonal Contraceptives Do Not Impact Economic Preferences: Evidence from a Randomized Trial. Management Science, 2018, 64, 4515-4532.	4.1	19
29	Redefine statistical significance. Nature Human Behaviour, 2018, 2, 6-10.	12.0	1,763
30	Sex hormones and economic decision making in the lab. , 2018, , 391-402.		0
31	Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nature Genetics, 2018, 50, 1112-1121.	21.4	1,835
32	Is research in social psychology politically biased? Systematic empirical tests and a forecasting survey to address the controversy. Journal of Experimental Social Psychology, 2018, 79, 188-199.	2.2	27
33	Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results. Advances in Methods and Practices in Psychological Science, 2018, 1, 337-356.	9.4	406
34	Evaluating the replicability of social science experiments in Nature and Science between 2010 and 2015. Nature Human Behaviour, 2018, 2, 637-644.	12.0	845
35	Datasets from a research project examining the role of politics in social psychological research. Scientific Data, 2018, 5, 180236.	5.3	0
36	Does Gender Diversity Promote Nonconformity?. Management Science, 2017, 63, 1085-1096.	4.1	27

#	Article	IF	Citations
37	Education and Social Trust: Testing a Causal Hypothesis Using the Discordant Twin Design. Political Psychology, 2017, 38, 515-531.	3.6	40
38	Registered Replication Report: Rand, Greene, and Nowak (2012). Perspectives on Psychological Science, 2017, 12, 527-542.	9.0	129
39	Subliminal influence on generosity. Experimental Economics, 2017, 20, 531-555.	2.1	12
40	A first-choice combined oral contraceptive influences general well-being in healthy women: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility, 2017, 107, 1238-1245.	1.0	57
41	The effect of fast and slow decisions on risk taking. Journal of Risk and Uncertainty, 2017, 54, 37-59.	1.5	73
42	Genome-wide association meta-analysis of 78,308 individuals identifies new loci and genes influencing human intelligence. Nature Genetics, 2017, 49, 1107-1112.	21.4	425
43	The psychometric and empirical properties of measures of risk preferences. Journal of Risk and Uncertainty, 2017, 54, 203-237.	1.5	82
44	Genotype–covariate interaction effects and the heritability of adult body mass index. Nature Genetics, 2017, 49, 1174-1181.	21.4	119
45	An epigenome-wide association study meta-analysis of educational attainment. Molecular Psychiatry, 2017, 22, 1680-1690.	7.9	70
46	Meta-GWAS Accuracy and Power (MetaGAP) Calculator Shows that Hiding Heritability Is Partially Due to Imperfect Genetic Correlations across Studies. PLoS Genetics, 2017, 13, e1006495.	3.5	78
47	Intuition and Moral Decision-Making – The Effect of Time Pressure and Cognitive Load on Moral Judgment and Altruistic Behavior. PLoS ONE, 2016, 11, e0164012.	2.5	91
48	Personality Polygenes, Positive Affect, and Life Satisfaction. Twin Research and Human Genetics, 2016, 19, 407-417.	0.6	16
49	Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. Nature Genetics, 2016, 48, 624-633.	21.4	870
50	Genome-wide association study identifies 74 loci associated with educational attainment. Nature, 2016, 533, 539-542.	27.8	1,204
51	Combined Oral Contraceptives and Sexual Function in Women—a Double-Blind, Randomized, Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4046-4053.	3.6	45
52	Genome-wide analysis identifies 12 loci influencing human reproductive behavior. Nature Genetics, 2016, 48, 1462-1472.	21.4	284
53	Estimating the Impact of Education on Political Participation: Evidence from Monozygotic Twins in the United States, Denmark and Sweden. Political Behavior, 2016, 38, 579-601.	2.7	27
54	Subjective Well-Being and Its Association with Subjective Health Status, Age, Sex, Region, and Socio-economic Characteristics in a Chinese Population Study. Journal of Happiness Studies, 2016, 17, 833-873.	3.2	121

#	Article	IF	CITATIONS
55	Evaluating replicability of laboratory experiments in economics. Science, 2016, 351, 1433-1436.	12.6	789
56	Can monetary incentives increase organ donations?. Economics Letters, 2016, 142, 56-58.	1.9	8
57	Discrimination against students with foreign backgrounds: evidence from grading in Swedish public high schools. Education Economics, 2015, 23, 660-676.	1.1	27
58	The Psychometric and Empirical Properties of Measures of Risk Preferences. SSRN Electronic Journal, 2015, , .	0.4	12
59	The association between lower educational attainment and depression owing to shared genetic effects? Results in ~25 000 subjects. Molecular Psychiatry, 2015, 20, 735-743.	7.9	59
60	Polygenic risk scores for schizophrenia and bipolar disorder predict creativity. Nature Neuroscience, 2015, 18, 953-955.	14.8	351
61	Using prediction markets to forecast research evaluations. Royal Society Open Science, 2015, 2, 150287.	2.4	7
62	Directional dominance on stature and cognition inÂdiverse human populations. Nature, 2015, 523, 459-462.	27.8	173
63	Assessing the Robustness of Power Posing. Psychological Science, 2015, 26, 653-656.	3.3	178
64	Estimating the reproducibility of psychological science. Science, 2015, 349, aac4716.	12.6	4,926
65	Using prediction markets to estimate the reproducibility of scientific research. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15343-15347.	7.1	206
65	Using prediction markets to estimate the reproducibility of scientific research. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15343-15347. Smoking is associated with mosaic loss of chromosome Y. Science, 2015, 347, 81-83.	7.1	206
	National Academy of Sciences of the United States of America, 2015, 112, 15343-15347.		
66	National Academy of Sciences of the United States of America, 2015, 112, 15343-15347. Smoking is associated with mosaic loss of chromosome Y. Science, 2015, 347, 81-83. Linking Genes and Political Orientations: Testing the Cognitive Ability as Mediator Hypothesis.	12.6	163
66	National Academy of Sciences of the United States of America, 2015, 112, 15343-15347. Smoking is associated with mosaic loss of chromosome Y. Science, 2015, 347, 81-83. Linking Genes and Political Orientations: Testing the Cognitive Ability as Mediator Hypothesis. Political Psychology, 2015, 36, 649-665. Pre-Birth Factors, Post-Birth Factors, and Voting: Evidence from Swedish Adoption Data. American	12.6 3.6	163
66 67 68	National Academy of Sciences of the United States of America, 2015, 112, 15343-15347. Smoking is associated with mosaic loss of chromosome Y. Science, 2015, 347, 81-83. Linking Genes and Political Orientations: Testing the Cognitive Ability as Mediator Hypothesis. Political Psychology, 2015, 36, 649-665. Pre-Birth Factors, Post-Birth Factors, and Voting: Evidence from Swedish Adoption Data. American Political Science Review, 2014, 108, 71-87. Common genetic variants associated with cognitive performance identified using the proxy-phenotype method. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111,	12.6 3.6 3.7	163 64 53
66 67 68	National Academy of Sciences of the United States of America, 2015, 112, 15343-15347. Smoking is associated with mosaic loss of chromosome Y. Science, 2015, 347, 81-83. Linking Genes and Political Orientations: Testing the Cognitive Ability as Mediator Hypothesis. Political Psychology, 2015, 36, 649-665. Pre-Birth Factors, Post-Birth Factors, and Voting: Evidence from Swedish Adoption Data. American Political Science Review, 2014, 108, 71-87. Common genetic variants associated with cognitive performance identified using the proxy-phenotype method. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13790-13794.	12.6 3.6 3.7 7.1	1636453244

#	Article	IF	CITATIONS
73	Replicability and Robustness of Genome-Wide-Association Studies for Behavioral Traits. Psychological Science, 2014, 25, 1975-1986.	3.3	92
74	The co-twin methodology and returns to schooling $\hat{a} \in \text{``}$ testing a critical assumption. Labour Economics, 2014, 26, 1-10.	1.7	25
75	The heritability of moral standards for everyday dishonesty. Journal of Economic Behavior and Organization, 2013, 93, 363-366.	2.0	22
76	Do people care about social context? Framing effects in dictator games. Experimental Economics, 2013, 16, 349-371.	2.1	147
77	Gender differences in social framing effects. Economics Letters, 2013, 118, 470-472.	1.9	37
78	Guest Editorsâ \in [™] Preface to the Special Symposium on Field Experiments. Scandinavian Journal of Economics, 2013, 115, 1-2.	1.4	1
79	GWAS of 126,559 Individuals Identifies Genetic Variants Associated with Educational Attainment. Science, 2013, 340, 1467-1471.	12.6	750
80	Intuition and cooperation reconsidered. Nature, 2013, 498, E1-E2.	27.8	200
81	Molecular genetics and subjective well-being. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9692-9697.	7.1	82
82	Distinct Loci in the <i>CHRNA5</i> / <i>CHRNA3</i> / <i>CHRNB4</i> Gene Cluster Are Associated With Onset of Regular Smoking. Genetic Epidemiology, 2013, 37, 846-859.	1.3	32
83	The Swedish Twin Registry: Establishment of a Biobank and Other Recent Developments. Twin Research and Human Genetics, 2013, 16, 317-329.	0.6	267
84	The Molecular Genetic Architecture of Self-Employment. PLoS ONE, 2013, 8, e60542.	2.5	41
85	The Behavioral Genetics of Behavioral Anomalies. Management Science, 2012, 58, 21-34.	4.1	100
86	Most Reported Genetic Associations With General Intelligence Are Probably False Positives. Psychological Science, 2012, 23, 1314-1323.	3.3	221
87	The Genetic Origins of the Relationship between Psychological Traits and Social Trust. Twin Research and Human Genetics, 2012, 15, 21-33.	0.6	66
88	The genetic architecture of economic and political preferences. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8026-8031.	7.1	225
89	Social framing effects: Preferences or beliefs?. Games and Economic Behavior, 2012, 76, 117-130.	0.8	192
90	Does parametric fMRI analysis with SPM yield valid results?â€"An empirical study of 1484 rest datasets. Neurolmage, 2012, 61, 565-578.	4.2	103

#	Article	IF	Citations
91	The Promises and Pitfalls of Genoeconomics. Annual Review of Economics, 2012, 4, 627-662.	5.5	168
92	Do People Care About Social Context? Framing Effects in Dictator Games. SSRN Electronic Journal, 2012, , .	0.4	7
93	Genetic and Environmental Influences on the Relationship between Flow Proneness, Locus of Control and Behavioral Inhibition. PLoS ONE, 2012, 7, e47958.	2.5	39
94	A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women. Fertility and Sterility, 2011, 95, 152-157.	1.0	41
95	Are boys discriminated in Swedish high schools?. Economics of Education Review, 2011, 30, 682-690.	1.4	72
96	Molecular Genetics and Economics. Journal of Economic Perspectives, 2011, 25, 57-82.	5.9	99
97	Conspicuous generosity. Journal of Public Economics, 2011, 95, 1131-1143.	4.3	77
98	Regional differences in health status in China: Population health-related quality of life results from the National Health Services Survey 2008. Health and Place, 2011, 17, 671-680.	3.3	72
99	Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Quality of Life Research, 2011, 20, 309-320.	3.1	188
100	On the sources of the height–intelligence correlation: New insights from a bivariate ACE model with assortative mating. Behavior Genetics, 2011, 41, 242-252.	2.1	48
101	Limbic Justiceâ€"Amygdala Involvement in Immediate Rejection in the Ultimatum Game. PLoS Biology, 2011, 9, e1001054.	5.6	111
102	The Effect of Competition on Physical Activity: A Randomized Trial. B E Journal of Economic Analysis and Policy, 2010, 10 , .	0.9	13
103	Genetic Variation in Financial Decisionâ€Making. Journal of Finance, 2010, 65, 1725-1754.	5.1	235
104	No Association between Oxytocin Receptor (OXTR) Gene Polymorphisms and Experimentally Elicited Social Preferences. PLoS ONE, 2010, 5, e11153.	2.5	88
105	Testing guilt aversion. Games and Economic Behavior, 2010, 68, 95-107.	0.8	219
106	Anchoring and cognitive ability. Economics Letters, 2010, 107, 66-68.	1.9	115
107	Eliciting Willingness to Pay without Bias using Follow-up Certainty Statements: Comparisons between Probably/Definitely and a 10-point Certainty Scale. Environmental and Resource Economics, 2009, 43, 473-502.	3.2	63
108	Bargaining over a Common Good with Private Information*. Scandinavian Journal of Economics, 2009, 111, 547-565.	1.4	4

#	Article	IF	Citations
109	Experimental Game Theory and Behavior Genetics. Annals of the New York Academy of Sciences, 2009, 1167, 66-75.	3.8	23
110	Trust and Truth. Economic Journal, 2009, 119, 252-276.	3.6	45
111	Heritability of Overconfidence. Journal of the European Economic Association, 2009, 7, 617-627.	3.5	55
112	A randomized trial of the effect of estrogen and testosterone on economic behavior. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6535-6538.	7.1	164
113	The aversion to lying. Journal of Economic Behavior and Organization, 2009, 70, 81-92.	2.0	283
114	Time is not money. Journal of Economic Behavior and Organization, 2009, 72, 96-102.	2.0	32
115	Higher cognitive ability is associated with lower entries in a p-beauty contest. Journal of Economic Behavior and Organization, 2009, 72, 171-175.	2.0	87
116	Genetic Variation in Preferences for Giving and Risk Taking < sup>*. Quarterly Journal of Economics, 2009, 124, 809-842.	8.6	381
117	Crowding Out in Blood Donation: Was Titmuss Right?. Journal of the European Economic Association, 2008, 6, 845-863.	3.5	525
118	Eliciting Willingness to Pay Without Bias: Evidence from a Field Experiment. Economic Journal, 2008, 118, 114-137.	3.6	273
119	Anticipated verbal feedback induces altruistic behavior. Evolution and Human Behavior, 2008, 29, 100-105.	2.2	105
120	Communication: Content or relationship?. Journal of Economic Behavior and Organization, 2008, 65, 409-419.	2.0	43
121	Gender differences in deception. Economics Letters, 2008, 99, 197-199.	1.9	333
122	Pride and Prejudice: The Human Side of Incentive Theory. American Economic Review, 2008, 98, 990-1008.	8.5	431
123	Heritability of cooperative behavior in the trust game. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3721-3726.	7.1	324
124	Heritability of ultimatum game responder behavior. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15631-15634.	7.1	204
125	Paying Respect. Journal of Economic Perspectives, 2007, 21, 135-149.	5.9	158
126	Is generosity involuntary?. Economics Letters, 2007, 94, 32-37.	1.9	125

#	Article	lF	CITATIONS
127	Is Altruism Paternalistic?. Economic Journal, 2007, 117, 761-781.	3.6	47
128	Deteriorating health status in Stockholm 1998–2002: results from repeated population surveys using the EQ-5D. Quality of Life Research, 2007, 16, 1547-1553.	3.1	63
129	A comparison of individual and social time trade-off values for health states in the general population. Health Policy, 2006, 76, 359-370.	3.0	106
130	Confidence interval estimation tasks and the economics of overconfidence. Journal of Economic Behavior and Organization, 2006, 61, 453-470.	2.0	72
131	Consumption and Health. The BE Journal of Macroeconomics, 2006, 6, 1-30.	0.6	19
132	Business cycles and mortality: results from Swedish microdata. Social Science and Medicine, 2005, 60, 205-218.	3.8	123
133	Increasing socio-economic inequalities in life expectancy and QALYs in Sweden 1980-1997. Health Economics (United Kingdom), 2005, 14, 831-850.	1.7	57
134	Does Impartial Deliberation Breed Fair Behavior?. Rationality and Society, 2005, 17, 116-136.	1.1	6
135	Sunk costs and fairness in incomplete information bargaining. Games and Economic Behavior, 2005, 50, 155-177.	0.8	30
136	Absolute Income, Relative Income, Income Inequality, and Mortality. Journal of Human Resources, 2004, 39, 228.	3.1	100
137	Promises, Threats and Fairness. Economic Journal, 2004, 114, 397-420.	3.6	418
138	Is There a Hold-up Problem?. Scandinavian Journal of Economics, 2004, 106, 475-494.	1.4	68
139	Health State Utilities in Gastroesophageal Reflux Disease Patients with Heartburn: A Study in Germany and Sweden. Medical Decision Making, 2004, 24, 40-52.	2.4	20
140	The value of the change in health in Sweden 1980/81 to 1996/97. Health Economics (United Kingdom), 2003, 12, 637-654.	1.7	31
141	Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value in Health, 2003, 6, 9-17.	0.3	948
142	A note on the effect of unemployment on mortality. Journal of Health Economics, 2003, 22, 505-518.	2.7	184
143	Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies. Pharmacoeconomics, 2003, 21, 39-48.	3.3	91
144	Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma. Pharmacoeconomics, 2002, 20, 257-265.	3.3	45

#	Article	IF	Citations
145	On the measurement of relative and absolute income-related health inequality. Social Science and Medicine, 2002, 55, 1923-1928.	3.8	114
146	Do Life-Saving Regulations Save Lives?. Journal of Risk and Uncertainty, 2002, 24, 231-249.	1.5	37
147	Hypothetical versus real willingness to pay in the health care sector: results from a field experiment. Journal of Health Economics, 2001, 20, 441-457.	2.7	170
148	Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy, 2001, 55, 51-69.	3.0	200
149	The relationship between happiness, health, and socio-economic factors: results based on Swedish microdata. Journal of Socio-Economics, 2001, 30, 553-557.	1.0	306
150	Time Preference for Health: A Test of Stationarity versus Decreasing Timing Aversion. Journal of Mathematical Psychology, 2001, 45, 265-282.	1.8	53
151	Should we aggregate relative or absolute changes in QALYs?. Health Economics (United Kingdom), 2001, 10, 573-577.	1.7	32
152	Swedish population health-related quality of life results using the EQ-5D. Quality of Life Research, 2001, 10, 621-635.	3.1	539
153	At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?. European Heart Journal, 2001, 22, 919-925.	2.2	57
154	Resource Utilization and Costs of Stroke Unit Care Integrated in a Care Continuum: A 1-Year Controlled, Prospective, Randomized Study in Elderly Patients. Stroke, 2000, 31, 2569-2577.	2.0	98
155	Health-related Quality of Life in Patients with Psoriasis and Atopic Dermatitis Measured with SF-36, DLQI and a Subjective Measure of Disease Activity. Acta Dermato-Venereologica, 2000, 80, 430-434.	1.3	199
156	Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus. Results from the DIGAMI study. European Heart Journal, 2000, 21, 733-739.	2.2	46
157	Non-reciprocal altruism in dictator games. Economics Letters, 2000, 69, 137-142.	1.9	56
158	Income-related inequality in life-years and quality-adjusted life-years. Journal of Health Economics, 2000, 19, 1007-1026.	2.7	80
159	A COMPUTER MODEL TO ANALYZE THE COST-EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY. International Journal of Technology Assessment in Health Care, 1999, 15, 352-365.	0.5	32
160	The Relationship between Health-state Utilities and the SF-12 in a General Population. Medical Decision Making, 1999, 19, 128-140.	2.4	103
161	Cost Benefit of Treating Hypertension. Clinical and Experimental Hypertension, 1999, 21, 987-997.	1.3	9
162	Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. British Journal of Dermatology, 1999, 141, 1067-1075.	1.5	180

#	Article	IF	CITATIONS
163	Calibrating Hypothetical Willingness to Pay Responses. Journal of Risk and Uncertainty, 1999, 18, 21-32.	1.5	83
164	Stated Preferences, Real Behaviour and Anchoring: Some Empirical Evidence. Environmental and Resource Economics, 1999, 13, 235-248.	3.2	32
165	The demand for health: results from new measures of health capital. European Journal of Political Economy, 1999, 15, 501-521.	1.8	59
166	New estimates of the demand for health: results based on a categorical health measure and Swedish micro data. Social Science and Medicine, 1999, 49, 1325-1332.	3.8	54
167	Probability Weighting and Utility Curvature in QALY-Based Decision Making. Journal of Mathematical Psychology, 1999, 43, 238-260.	1.8	40
168	A comparison of patient and social tariff values derived from the time trade-off method., 1999, 8, 541-545.		33
169	Inconsistencies in the "Societal Perspective" on Costs of the Panel on Cost-Effectiveness in Health and Medicine. Medical Decision Making, 1999, 19, 371-377.	2.4	91
170	A note on validating Wagstaff and van Doorslaer's health measure in the analysis of inequalities in health. Journal of Health Economics, 1999, 18, 117-124.	2.7	49
171	On aggregating QALYs: a comment on Dolan. Journal of Health Economics, 1999, 18, 381-386.	2.7	10
172	Use of contingent valuation to place a monetary value on pharmacy services: An overview and review of the literature. Clinical Therapeutics, 1999, 21, 1402-1417.	2.5	37
173	Methodology. Health-state utilities in a general population in relation to age, gender and socioeconomic factors. European Journal of Public Health, 1999, 9, 211-217.	0.3	51
174	Cost-effectiveness analysis and capital costs. Social Science and Medicine, 1998, 46, 1183-1191.	3.8	15
175	Editorial: Some reflections on cost-effectiveness analysis. , 1998, 7, 1-7.		120
176	Perceptions and preferences of autologous blood donors. Transfusion, 1998, 38, 757-763.	1.6	31
177	Cystic fibrosis through a female perspective: Psychosocial issues and information concerning puberty and motherhood. Patient Education and Counseling, 1998, 34, 115-123.	2.2	40
178	Time spent on waiting lists for medical care: an insurance approach. Journal of Health Economics, 1998, 17, 627-644.	2.7	44
179	Effects of user charges on the use of prescription medicines in different socio-economic groups. Health Policy, 1998, 44, 123-134.	3.0	51
180	An experimental test of question framing in health state utility assessment. Health Policy, 1998, 45, 187-193.	3.0	15

#	Article	IF	CITATIONS
181	Relationship Between Quality of Life Instruments, Health State Utilities, and Willingness to Pay in Patients with Asthma. Annals of Allergy, Asthma and Immunology, 1998, 80, 189-194.	1.0	103
182	An experimental comparison of dichotomous choice contingent valuation questions and real purchase decisions. Applied Economics, 1998, 30, 643-647.	2.2	150
183	Price Indices of Drugs and the Switching to New Drugs. Pharmacoeconomics, 1998, 13, 71-80.	3.3	6
184	The Effect of Changes in Treatment Patterns on Drug Expenditure. Pharmacoeconomics, 1998, 13, 127-134.	3.3	29
185	Urge Incontinence. Pharmacoeconomics, 1998, 14, 531-539.	3.3	67
186	Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation. Southern Economic Journal, 1998, 65, 169.	2.1	109
187	Female patients with cystic fibrosis suffer from reproductive endocrinological disorders despite good clinical status. Human Reproduction, 1998, 13, 2092-2097.	0.9	64
188	Economics, Pharmaceuticals, and Pharmacoeconomics. Medical Decision Making, 1998, 18, S1-S3.	2.4	6
189	A Note on Confidence Intervals in Cost-Effectiveness Analysis. International Journal of Technology Assessment in Health Care, 1998, 14, 467-471.	0.5	135
190	The value of changes in health risks: a review. , 1998, , 101-120.		0
190 191	The value of changes in health risks: a review. , 1998, , 101-120. Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation. Southern Economic Journal, 1998, 65, 169-177.	2.1	0
	Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation. Southern	2.1	
191	Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation. Southern Economic Journal, 1998, 65, 169-177. The Impact of Risk Information on Patients' Willingness to Pay for Autologous Blood Donation.		106
191	Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation. Southern Economic Journal, 1998, 65, 169-177. The Impact of Risk Information on Patients' Willingness to Pay for Autologous Blood Donation. Medical Care, 1998, 36, 1162-1173.	2.4	106
191 192 193	Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation. Southern Economic Journal, 1998, 65, 169-177. The Impact of Risk Information on Patients' Willingness to Pay for Autologous Blood Donation. Medical Care, 1998, 36, 1162-1173. Delayed Puberty in Girls With Cystic Fibrosis Despite Good Clinical Status. Pediatrics, 1997, 99, 29-34.	2.4	106 28 112
191 192 193	Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation. Southern Economic Journal, 1998, 65, 169-177. The Impact of Risk Information on Patients' Willingness to Pay for Autologous Blood Donation. Medical Care, 1998, 36, 1162-1173. Delayed Puberty in Girls With Cystic Fibrosis Despite Good Clinical Status. Pediatrics, 1997, 99, 29-34. The Validity of QALYs. Medical Decision Making, 1997, 17, 21-32. An Experimental Test of a Theoretical Foundation for Rating-scale Valuations. Medical Decision	2.4 2.1 2.4	106 28 112 110
191 192 193 194	Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation. Southern Economic Journal, 1998, 65, 169-177. The Impact of Risk Information on Patients' Willingness to Pay for Autologous Blood Donation. Medical Care, 1998, 36, 1162-1173. Delayed Puberty in Girls With Cystic Fibrosis Despite Good Clinical Status. Pediatrics, 1997, 99, 29-34. The Validity of QALYs. Medical Decision Making, 1997, 17, 21-32. An Experimental Test of a Theoretical Foundation for Rating-scale Valuations. Medical Decision Making, 1997, 17, 208-216. Incorporating Future Costs in Medical Cost-Effectiveness Analysis. Medical Decision Making, 1997, 17,	2.4 2.1 2.4	106 28 112 110

#	Article	IF	CITATIONS
199	The value of life extension and the marginal rate of time preference: a pilot study. Applied Economics Letters, 1997, 4, 53-55.	1.8	9
200	Cystic fibrosis mRNA expression in rat brain. NeuroReport, 1997, 8, 535-539.	1.2	41
201	Some further experimental results on hypothetical versus real willingness to pay. Applied Economics Letters, 1997, 4, 535-536.	1.8	20
202	Hypothetical versus real willingness to pay: some experimental results. Applied Economics Letters, 1997, 4, 149-151.	1.8	33
203	Avoiding Double-Counting in Pharmacoeconomic Studies. Pharmacoeconomics, 1997, 11, 385-388.	3.3	51
204	Cost Effectiveness and Allocation of Therapies in a Treating Population. Pharmacoeconomics, 1997, 11, 606-606.	3.3	0
205	Polymorphic Expression of Multidrug Resistance mRNA in Lung Parenchyma of Nonpregnant and Pregnant Rats: A Comparison to Cystic Fibrosis mRNA Expression. Biochemical and Biophysical Research Communications, 1997, 239, 606-611.	2.1	9
206	Hypothetical versus real payments in Vickrey auctions. Economics Letters, 1997, 56, 177-180.	1.9	31
207	Standard gamble, time trade-off and rating scale: Experimental results on the ranking properties of QALYs. Journal of Health Economics, 1997, 16, 155-175.	2.7	139
208	Is the valuation of a QALY gained independent of age? Some empirical evidence. Journal of Health Economics, 1997, 16, 589-599.	2.7	109
209	The friction cost method: A comment. Journal of Health Economics, 1997, 16, 249-255.	2.7	147
210	Cost-utility analysis from a societal perspective. Health Policy, 1997, 39, 241-253.	3.0	43
211	Patients' willingness to pay for autologous blood donation. Health Policy, 1997, 40, 1-12.	3.0	40
212	The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy, 1997, 41, 105-119.	3.0	56
213	A note on prevention versus cure. Health Policy, 1997, 41, 181-187.	3.0	10
214	Cost-utility analysis and varying preferences for health. Health Policy, 1997, 41, 201-205.	3.0	5
215	The impact of hormone replacement therapy on quality of life and willingness to pay. BJOG: an International Journal of Obstetrics and Gynaecology, 1997, 104, 1191-1195.	2.3	71
216	Quality of life and the WTP for an increased life expectancy at an advanced age. Journal of Public Economics, 1997, 65, 219-228.	4.3	62

#	Article	IF	CITATIONS
217	On the Value of Changes in Life Expectancy: Blips Versus Parametric Changes. Journal of Risk and Uncertainty, 1997, 15, 221-239.	1.5	90
218	Characterizing QALYs by Risk Neutrality. Journal of Risk and Uncertainty, 1997, 15, 107-114.	1.5	99
219	Saving lives in the present versus saving lives in the futureis there a framing effect?. , 1997, 15, 167-176.		13
220	Willingness to pay for reduced incontinence symptoms. BJU International, 1997, 80, 557-562.	2.5	74
221	Contingent valuation with an open-ended follow-up question: a test of scope effects. , 1997, 6, 637-639.		11
222	Interpretation of change scores in ordinal clinical scales and health status measures: The whole may not equal the sum of the parts. Journal of Clinical Epidemiology, 1996, 49, 711-717.	5.0	193
223	A note on the estimation of the equity-efficiency trade-off for QALYs. Journal of Health Economics, 1996, 15, 359-368.	2.7	68
224	Incorporating quality of life changes into economic evaluations of health care: an overview. Health Policy, 1996, 36, 155-166.	3.0	12
225	The willingness to pay for health changes, the human-capital approach and the external costs. Health Policy, 1996, 36, 231-244.	3.0	54
226	The economics of ageing: on the attitude of Swedish people to the distribution of health care resources between the young and the old. Health Policy, 1996, 37, 153-161.	3.0	31
227	Use of Misoprostol in the Elderly. Drugs and Aging, 1996, 8, 84-88.	2.7	9
228	The Decision Rules of Cost-Effectiveness Analysis. Pharmacoeconomics, 1996, 9, 113-120.	3.3	165
229	The Impact of User Charges on the Consumption of Drugs. Pharmacoeconomics, 1996, 9, 478-483.	3.3	13
230	Economic Evaluation in Healthcare. Pharmacoeconomics, 1996, 10, 114-122.	3.3	26
231	Cost-effectiveness of cholesterol lowering: Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal, 1996, 17, 1001-1007.	2.2	160
232	A note on the relationship between ex ante and expected willingness to pay for health care. Social Science and Medicine, 1996, 42, 305-311.	3.8	29
233	The cost effectiveness of lipid lowering in Swedish primary health care. Journal of Internal Medicine, 1996, 240, 23-29.	6.0	38
234	Outcome measurement in economic evaluation. Health Economics (United Kingdom), 1996, 5, 279-296.	1.7	148

#	Article	IF	CITATIONS
235	The discounting of lives saved in future generationsâ€"some empirical results. Health Economics (United Kingdom), 1996, 5, 329-332.	1.7	25
236	Valuation of health changes with the contingent valuation method: A test of scope and question order effects., 1996, 5, 531-541.		57
237	The value of private safety versus the value of public safety. Journal of Risk and Uncertainty, 1996, 13, 263-275.	1.5	92
238	To be, or not to be, that is the question: An empirical study of the WTP for an increased life expectancy at an advanced age. Journal of Risk and Uncertainty, 1996, 13, 163-174.	1.5	94
239	Willingness to Pay for Reductions in Angina Pectoris Attacks. Medical Decision Making, 1996, 16, 248-253.	2.4	83
240	Outcome measurement in economic evaluation. Health Economics (United Kingdom), 1996, 5, 279-296.	1.7	1
241	Valuation of health changes with the contingent valuation method: A test of scope and question order effects. Health Economics (United Kingdom), 1996, 5, 531-541.	1.7	2
242	Theory and Methods of Economic Evaluation of Health Care. Developments in Health Economics and Public Policy, $1996, , .$	0.4	115
243	The Expressed Preference Approach. Developments in Health Economics and Public Policy, 1996, , 75-100.	0.4	1
244	Economic Evaluation and Policy Making. Developments in Health Economics and Public Policy, 1996, , 221-236.	0.4	0
245	Cost-Effectiveness Analysis. Developments in Health Economics and Public Policy, 1996, , 135-172.	0.4	0
246	Cost-Utility Analysis. Developments in Health Economics and Public Policy, 1996, , 173-220.	0.4	0
247	The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment. Journal of Human Hypertension, 1996, 10 Suppl 2, S23-6.	2.2	5
248	Theory and methods of economic evaluation of health care. Developments in Health Economics and Public Policy, 1996, 4, 1-245.	0.4	28
249	The discounting of lives saved in future generations—some empirical results. Health Economics (United Kingdom), 1996, 5, 329-332.	1.7	0
250	The Ranking Properties of Healthy-Years Equivalents and Quality-Adjusted Life-Years Under Certainty and Uncertainty. International Journal of Technology Assessment in Health Care, 1995, 11, 40-48.	0.5	27
251	The costs and effects of two different lipid intervention programmes in primary health care. Journal of Internal Medicine, 1995, 237, 13-17.	6.0	12
252	The costâ€effectiveness of a cardiovascular multipleâ€riskâ€factor intervention programme in treated hypertensive men. Journal of Internal Medicine, 1995, 237, 19-26.	6.0	28

#	Article	IF	CITATIONS
253	Qalys: A comment. Journal of Public Economics, 1995, 56, 327-328.	4.3	4
254	The relationship between cost-effectiveness analysis and cost-benefit analysis. Social Science and Medicine, 1995, 41, 483-489.	3.8	89
255	Has the Cost-effectiveness of Misoprostol Been Underestimated?-Reply. Archives of Internal Medicine, 1995, 155, 1451.	3.8	1
256	Quality-adjusted life-years versus healthy-years equivalents $\hat{a} \in \text{``}$ A comment. Journal of Health Economics, 1995, 14, 9-16.	2.7	23
257	A note on the depreciation of the societal perspective in economic evaluation of health care. Health Policy, 1995, 33, 59-66.	3.0	31
258	Economic evaluation of health care and policymaking. Health Policy, 1995, 33, 179-190.	3.0	16
259	Value for money? A contingent valuation study of the optimal size of the Swedish health care budget. Health Policy, 1995, 34, 135-143.	3.0	22
260	On the estimation of cost-effectiveness ratios. Health Policy, 1995, 31, 225-229.	3.0	18
261	A pilot test of using the veil of ignorance approach to estimate a social welfare function for income. Applied Economics Letters, 1995, 2, 400-402.	1.8	12
262	The Cost Effectiveness of Hypertension Treatment in Sweden. Pharmacoeconomics, 1995, 7, 242-250.	3.3	47
263	Economic Evaluation of Drugs and its Potential Uses in Policy Making. Pharmacoeconomics, 1995, 8, 190-198.	3.3	24
264	The Impact of Age on the Cost - Effectiveness of Hypertension Treatment. Medical Decision Making, 1994, 14, 236-244.	2.4	32
265	A Note on QALYs, Time Tradeoff, and Discounting. Medical Decision Making, 1994, 14, 188-193.	2.4	93
266	QALYs, HYEs and individual preferencesâ€" A graphical illustration. Social Science and Medicine, 1994, 39, 1623-1632.	3.8	16
267	The cost-effectiveness of the switch towards more expensive antihypertensive drugs. Health Policy, 1994, 28, 1-13.	3.0	19
268	The Concept of Cost in the Economic Evaluation of Health Care: <i> A Theoretical Inquiry </i> International Journal of Technology Assessment in Health Care, 1994, 10, 675-682.	0.5	22
269	From Principle To Public Policy: Using Cost-Effectiveness Analysis. Health Affairs, 1994, 13, 206-214.	5.2	21
270	The Willingness to Pay for In Vitro Fertilization: A Pilot Study Using Contingent Valuation. Medical Care, 1994, 32, 686-699.	2.4	163

#	Article	IF	CITATIONS
271	Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Archives of Internal Medicine, 1994, 154, 2020-2025.	3.8	4
272	Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Archives of Internal Medicine, 1994, 154, 2020-5.	3.8	10
273	The contingent valuation method—appraising the appraisers. Health Economics (United Kingdom), 1993, 2, 357-359.	1.7	11
274	The costâ€effectiveness of treating hypertension in elderly peopleâ€"an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Journal of Internal Medicine, 1993, 234, 317-323.	6.0	61
275	On the decision rules of cost-effectiveness analysis. Journal of Health Economics, 1993, 12, 459-467.	2.7	247
276	Willingness to pay for antihypertensive therapy â€" further results. Journal of Health Economics, 1993, 12, 95-108.	2.7	114
277	Cost-Effectiveness of Antihypertensive Treatment. Pharmacoeconomics, 1993, 3, 36-44.	3.3	14
278	Drug Expenditure and New Drug Introductions. Pharmacoeconomics, 1993, 4, 215-225.	3.3	12
279	Economic evaluation of osteoporosis prevention. Health Policy, 1993, 24, 103-124.	3.0	16
280	Willingness to pay for lipid lowering: a health production function approach. Applied Economics, 1993, 25, 1023-1031.	2.2	39
281	The cost of screening for hypercholesterolaemia– results from a clinical trial in Swedish primary health care. Scandinavian Journal of Clinical and Laboratory Investigation, 1993, 53, 725-732.	1.2	13
282	Are Healthy-years Equivalents an Improvement over Quality-adjusted Life Years?. Medical Decision Making, 1993, 13, 281-286.	2.4	61
283	The Contingent-valuation Method. Medical Decision Making, 1993, 13, 311-312.	2.4	10
284	Economic Evaluation of Hypertension Treatment. International Journal of Technology Assessment in Health Care, 1992, 8, 506-523.	0.5	21
285	On the Discounting of Gained life-Years in Cost-Effectiveness Analysis. International Journal of Technology Assessment in Health Care, 1992, 8, 359-364.	0.5	29
286	A health-economic comparison of diet and drug treatment in obese men with mild hypertension. Journal of Hypertension, 1992, 10, 1063???1070.	0.5	39
287	A Review of Cost-Effectiveness Analyses of Hypertension Treatment. Pharmacoeconomics, $1992, 1, 250-264$.	3.3	40
288	Economic Evaluation of Drug Therapy. Pharmacoeconomics, 1992, 1, 325-337.	3.3	20

#	Article	lF	CITATIONS
289	The Australian Guidelines for Subsidisation of Pharmaceuticals. Pharmacoeconomics, 1992, 2, 355-362.	3.3	21
290	Economic evaluation of lipid lowering $\hat{a}\in$ " A feasibility test of the contingent valuation approach. Health Policy, 1992, 20, 309-320.	3.0	34
291	A health-economic comparison of diet and drug treatment in obese men with mild hypertension. Journal of Hypertension, 1992, 10, 1063-70.	0.5	8
292	The costs of treating hypertension â€" an analysis of different cut-off points. Health Policy, 1991, 18, 141-150.	3.0	40
293	Economic evaluation in health care: Is there a role for cost-benefit analysis?. Health Policy, 1991, 17, 1-23.	3.0	175
294	The Costs of Treating Hypertension in Sweden. Scandinavian Journal of Primary Health Care, 1991, 9, 155-160.	1.5	42
295	Willingness to pay for antihypertensive therapy â€" results of a Swedish pilot study. Journal of Health Economics, 1991, 10, 461-473.	2.7	168
296	Cost-effectiveness analysis of hypertension treatment $\hat{a} \in$ A review of methodological issues. Health Policy, 1991, 19, 55-77.	3.0	49
297	A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Medical Informatics = Medecine Et Informatique, 1991, 16, 355-362.	0.8	33
298	Costâ€benefit analysis of nonâ€pharmacological treatment of hypertension. Journal of Internal Medicine, 1991, 230, 307-312.	6.0	41
299	Eliciting Willingness to Pay Without Bias Using Follow-Up Certainty Statements: Comparisons Between Probably/Definitely and a 10-Point Certainty Scale. SSRN Electronic Journal, 0, , .	0.4	0
300	Generosity and Political Preferences. SSRN Electronic Journal, 0, , .	0.4	6
301	Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?. SSRN Electronic Journal, 0, , .	0.4	27